190 related articles for article (PubMed ID: 20802293)
1. Resistance analyses in highly experienced patients failing raltegravir, etravirine and darunavir/ritonavir regimen.
Charpentier C; Roquebert B; Colin C; Taburet AM; Fagard C; Katlama C; Molina JM; Jacomet C; Brun-Vézinet F; Chêne G; Yazdanpanah Y; Descamps D;
AIDS; 2010 Nov; 24(17):2651-6. PubMed ID: 20802293
[TBL] [Abstract][Full Text] [Related]
2. Resistant minority species are rarely observed in patients on darunavir/ritonavir monotherapy.
Lambert-Niclot S; Flandre P; Valantin MA; Peytavin G; Sayon S; Morand-Joubert L; Delaugerre C; Algarte-Genin M; Katlama C; Calvez V; Marcelin AG
J Antimicrob Chemother; 2012 Jun; 67(6):1470-4. PubMed ID: 22396434
[TBL] [Abstract][Full Text] [Related]
3. Highly frequent HIV-1 minority resistant variants at baseline of the ANRS 139 TRIO trial had a limited impact on virological response.
Charpentier C; Lee GQ; Rodriguez C; Visseaux B; Storto A; Fagard C; Molina JM; Katlama C; Yazdanpanah Y; Harrigan PR; Descamps D
J Antimicrob Chemother; 2015 Jul; 70(7):2090-6. PubMed ID: 25755001
[TBL] [Abstract][Full Text] [Related]
4. High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial.
Yazdanpanah Y; Fagard C; Descamps D; Taburet AM; Colin C; Roquebert B; Katlama C; Pialoux G; Jacomet C; Piketty C; Bollens D; Molina JM; Chêne G;
Clin Infect Dis; 2009 Nov; 49(9):1441-9. PubMed ID: 19814627
[TBL] [Abstract][Full Text] [Related]
5. Etravirine in combination with darunavir/ritonavir and optimized background regimen results in suppression of HIV replication in treatment-experienced patients. Evaluation of Katlama C, Haubrich R, Lalezari J, et al. Efficacy and safety of etravirine in treatment-experienced HIV-1 patients: pooled 48-week analysis of two randomized, controlled trials. AIDS 2009; 23: 2289-300.
Hull MW; Montaner JS
Expert Opin Pharmacother; 2010 Jun; 11(8):1433-7. PubMed ID: 20367279
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of darunavir/ritonavir plus etravirine dual regimen in antiretroviral therapy-experienced patients: a multicenter clinical experience.
Gazzola L; Cicconi P; Ripamonti D; Di Filippo E; Gustinetti G; Di Biagio A; Marchetti G; Bini T; d'Arminio Monforte A
HIV Clin Trials; 2014; 15(4):140-50. PubMed ID: 25143023
[TBL] [Abstract][Full Text] [Related]
7. A cohort study of treatment-experienced HIV-1-infected patients treated with raltegravir: factors associated with virological response and mutations selected at failure.
Marcelin AG; Delaugerre C; Beaudoux C; Descamps D; Morand-Joubert L; Amiel C; Schneider V; Ferre V; Izopet J; Si-Mohamed A; Maillard A; Henquell C; Desbois D; Lazrek M; Signori-Schmuck A; Rogez S; Yerly S; Trabaud MA; Plantier JC; Fourati S; Houssaini A; Masquelier B; Calvez V; Flandre P;
Int J Antimicrob Agents; 2013 Jul; 42(1):42-7. PubMed ID: 23562640
[TBL] [Abstract][Full Text] [Related]
8. Mutations associated with virological response to darunavir/ritonavir in HIV-1-infected protease inhibitor-experienced patients.
Descamps D; Lambert-Niclot S; Marcelin AG; Peytavin G; Roquebert B; Katlama C; Yeni P; Felices M; Calvez V; Brun-Vézinet F
J Antimicrob Chemother; 2009 Mar; 63(3):585-92. PubMed ID: 19147519
[TBL] [Abstract][Full Text] [Related]
9. Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis.
Boyd MA; Moore CL; Molina JM; Wood R; Madero JS; Wolff M; Ruxrungtham K; Losso M; Renjifo B; Teppler H; Kelleher AD; Amin J; Emery S; Cooper DA;
Lancet HIV; 2015 Feb; 2(2):e42-51. PubMed ID: 26424460
[TBL] [Abstract][Full Text] [Related]
10. Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART.
Lambert-Niclot S; George EC; Pozniak A; White E; Schwimmer C; Jessen H; Johnson M; Dunn D; Perno CF; Clotet B; Plettenberg A; Blaxhult A; Palmisano L; Wittkop L; Calvez V; Marcelin AG; Raffi F;
J Antimicrob Chemother; 2016 Apr; 71(4):1056-62. PubMed ID: 26702926
[TBL] [Abstract][Full Text] [Related]
11. Impact of lopinavir/ritonavir use on antiretroviral resistance in recent clinical practice.
Lambert-Niclot S; Masquelier B; Cohen Codar I; Soulie C; Delaugerre C; Morand-Joubert L; Charpentier C; Ferre V; Plantier JC; Montes B; Carret S; Perrot V; Peytavin G; Costagliola D; Calvez V; Marcelin AG;
J Antimicrob Chemother; 2012 Oct; 67(10):2487-93. PubMed ID: 22733652
[TBL] [Abstract][Full Text] [Related]
12. Role of baseline HIV-1 DNA level in highly-experienced patients receiving raltegravir, etravirine and darunavir/ritonavir regimen (ANRS139 TRIO trial).
Charpentier C; Fagard C; Colin C; Katlama C; Molina JM; Jacomet C; Visseaux B; Taburet AM; Brun-Vézinet F; Chêne G; Yazdanpanah Y; Descamps D;
PLoS One; 2013; 8(1):e53621. PubMed ID: 23349724
[TBL] [Abstract][Full Text] [Related]
13. Virological analysis of once-daily and twice-daily darunavir/ritonavir in the ODIN trial of treatment-experienced patients.
Lathouwers E; De La Rosa G; Van de Casteele T; Baeten B; Tomaka F; De Meyer S; Picchio G
Antivir Ther; 2013; 18(3):289-300. PubMed ID: 23558157
[TBL] [Abstract][Full Text] [Related]
14. Virological response to darunavir/ritonavir-based regimens in antiretroviral-experienced patients (PREDIZISTA study).
Pellegrin I; Wittkop L; Joubert LM; Neau D; Bollens D; Bonarek M; Girard PM; Fleury H; Winters B; Saux MC; Pellegrin JL; Thiébaut R; Breilh D;
Antivir Ther; 2008; 13(2):271-9. PubMed ID: 18505178
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance.
Boffito M; Winston A; Jackson A; Fletcher C; Pozniak A; Nelson M; Moyle G; Tolowinska I; Hoetelmans R; Miralles D; Gazzard B
AIDS; 2007 Jul; 21(11):1449-55. PubMed ID: 17589191
[TBL] [Abstract][Full Text] [Related]
16. Novel antiretroviral combinations in treatment-experienced patients with HIV infection: rationale and results.
Taiwo B; Murphy RL; Katlama C
Drugs; 2010 Sep; 70(13):1629-42. PubMed ID: 20731472
[TBL] [Abstract][Full Text] [Related]
17. The Intelence aNd pRezista Once A Day Study (INROADS): a multicentre, single-arm, open-label study of etravirine and darunavir/ritonavir as dual therapy in HIV-1-infected early treatment-experienced subjects.
Ruane PJ; Brinson C; Ramgopal M; Ryan R; Coate B; Cho M; Kakuda TN; Anderson D;
HIV Med; 2015 May; 16(5):288-96. PubMed ID: 25585528
[TBL] [Abstract][Full Text] [Related]
18. Factors predictive of successful darunavir/ritonavir-based therapy in highly antiretroviral-experienced HIV-1-infected patients (the DARWEST study).
Delaugerre C; Buyck JF; Peytavin G; Viard JP; Chaix ML; Zucman D; Mortier E; Blanche S; Rouveix E; Force G; Aegerter P; de Truchis P
J Clin Virol; 2010 Mar; 47(3):248-52. PubMed ID: 20097121
[TBL] [Abstract][Full Text] [Related]
19. Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruption.
Canducci F; Barda B; Ceresola E; Spagnuolo V; Sampaolo M; Boeri E; Nozza S; Cossarin F; Galli A; Gianotti N; Castagna A; Lazzarin A; Clementi M
Clin Microbiol Infect; 2011 Jun; 17(6):928-34. PubMed ID: 20854427
[TBL] [Abstract][Full Text] [Related]
20. Drugs in traditional drug classes (nucleoside reverse transcriptase inhibitor/nonnucleoside reverse transcriptase inhibitor/protease inhibitors) with activity against drug-resistant virus (tipranavir, darunavir, etravirine).
Arribas JR
Curr Opin HIV AIDS; 2009 Nov; 4(6):507-12. PubMed ID: 20048718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
